Keywords: Orexo, Invida, Abstral, Licensing, GlaxoSmithKline, Bilastine, Menarini, Faes Farma

Orexo licenses Abstral to Invida for in Asia Pacific: GlaxoSmithKline gets rights to bilastine in Spain and Poland

Article | 17 January 2011

Print This

Sweden’s Orexo AB (STO:ORX) has signed an exclusive licensing and distribution agreement with the Singapore-based Invida Group, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in